Amgen gets subpoena from NY AG
Pharma Compliance Alert, May 30, 2007
Amgen received a subpoena from New York's attorney general, it said last week in a Securities and Exchange Commission (SEC) filing. The subpoena seeks documents related to the company's promotional, sales and marketing activities, medical education, clinical studies, pricing and contracting, license and distribution agreements, and corporate communications.
Amgen's SEC filing also said that the company received a letter from the Senate Finance Committee "requesting a briefing to discuss the issues and concerns reported in the media" related to the marketing and safety of erythropoiesis stimulating agents. Amgen said Ranking Member Chuck Grassley (R-IA) requested documents and discussion about data requested by the FDA, Amgen's responses to those requests, and other information regarding clinical trials and adverse events. Amgen says it will fully cooperate.
Finally, Amgen said on May 11, a class action shareholder litigation suit was filed against it and several individual defendants alleging "false statements that resulted in a fraudulent scheme and course of business operated as a fraud or deceit on purchasers of Amgen publicly traded securities." It also alleges off-label marketing and failure to disclose negative results of clinical studies. Amgen said in the SEC filing that it had not yet been served with the complaint.
Read more on the SEC Web site.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- What does case-mix index mean to you?
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Searched